Baxter International
BAXTER INTERNATIONAL INC.
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$11.2B
Operating marginCalculated
-2.7%
Net assets to total assetsCalculated
30.6%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★☆☆☆☆position among all companies
-2.7%
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-1.9%
Capital efficiency
★☆☆☆☆position among all companies
-15.6%
Revenue and profit
Performance, financial position and capital allocation
Baxter International
Recent performance trends
Baxter International
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$12.1 billion | US$10.1 billion | US$10.4 billion | US$10.6 billion | US$11.2 billion |
| Operating income | US$1.4 billion | US$-2.8 billion | US$0.7 billion | US$14.00 million | US$-0.3 billion |
| Net income | US$1.3 billion | US$-2.4 billion | US$2.7 billion | US$-0.6 billion | US$-1.0 billion |
| Total assets | US$33.5 billion | US$28.3 billion | US$28.3 billion | US$25.8 billion | US$20.1 billion |
| Shareholders' equity | US$9.1 billion | US$5.8 billion | US$8.4 billion | US$7.0 billion | US$6.1 billion |
| Net cash provided by (used in) operating activities | US$2.2 billion | US$1.2 billion | US$1.7 billion | US$1.0 billion | US$0.8 billion |
| Net cash provided by (used in) investing activities | US$-11.2 billion | US$-0.9 billion | US$3.2 billion | US$-0.6 billion | US$2.8 billion |
| Net cash provided by (used in) financing activities | US$8.2 billion | US$-1.4 billion | US$-3.5 billion | US$-1.1 billion | US$-4.2 billion |
| Cash and cash equivalents | US$3.0 billion | US$1.6 billion | US$3.1 billion | US$1.8 billion | US$2.0 billion |
Revenue scale in the same industry
Baxter International
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 7 companies
- 11 Boston ScientificFY Dec 2025 US$20.1B
- 12 KLAFY Jun 2026 US$13.6B
- 13 Baxter InternationalThis companyFY Dec 2025 US$11.2B
- 14 Intuitive SurgicalFY Dec 2025 US$10.1B
- 15 Rockwell AutomationFY Sep 2025 US$8.3B
- … 28 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.5 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$2.0 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-4.2 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$2.8 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$0.8 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$1.0 billion | Consolidated | Disclosed |
| Dividends paid | US$0.3 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$6.1 billion | Consolidated | Disclosed |
| Non-controlling interests | US$-27.00 million | Consolidated | Disclosed |
| Net assets | US$6.1 billion | Consolidated | Disclosed |
| Net sales | US$11.2 billion | Consolidated | Disclosed |
| Operating income | US$-0.3 billion | Consolidated | Disclosed |
| Net income | US$-1.0 billion | Consolidated | Disclosed |
| Total assets | US$20.1 billion | Consolidated | Disclosed |
| Operating margin | -2.7% | Consolidated | Calculated |
| Net assets to total assets | 30.6% | Consolidated | Calculated |
| Net margin | -8.5% | Consolidated | Calculated |
| Return on equity | -15.6% | Consolidated | Calculated |